메뉴 건너뛰기




Volumn 65, Issue 1, 2012, Pages 1-7

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MOLECULAR MARKER; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN RECEPTOR;

EID: 84355161627     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200275     Document Type: Review
Times cited : (38)

References (116)
  • 1
    • 84957940642 scopus 로고    scopus 로고
    • Fact Sheet 297
    • WHO. Cancer. Fact Sheet 297. 2006. http://www.who.int/mediacentre/ factsheets/ fs297/en/index.html.
    • (2006) Cancer
  • 2
    • 53749097825 scopus 로고    scopus 로고
    • Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials
    • NSCLC Meta-Analyses Collaborative Group
    • NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25.
    • (2008) J Clin Oncol , vol.26 , pp. 4617-4625
  • 3
    • 44249086425 scopus 로고    scopus 로고
    • Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship
    • DOI 10.4065/83.5.584
    • Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94. (Pubitemid 351720831)
    • (2008) Mayo Clinic Proceedings , vol.83 , Issue.5 , pp. 584-594
    • Molina, J.R.1    Yang, P.2    Cassivi, S.D.3    Schild, S.E.4    Adjei, A.A.5
  • 5
    • 65349116059 scopus 로고    scopus 로고
    • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial
    • Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31.
    • (2009) Lancet , vol.373 , pp. 1525-1531
    • Pirker, R.1    Pereira, J.R.2    Szczesna, A.3
  • 6
    • 77949891126 scopus 로고    scopus 로고
    • Cetuximab and first-line taxane/ carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099
    • Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/ carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-17.
    • (2010) J Clin Oncol , vol.28 , pp. 911-917
    • Lynch, T.J.1    Patel, T.2    Dreisbach, L.3
  • 8
    • 0034949214 scopus 로고    scopus 로고
    • A biological staging model for operable non-small cell lung cancer
    • DOI 10.1136/thorax.56.7.561
    • Cox G, Jones JL, Andi A, et al. A biological staging model for operable non-small cell lung cancer. Thorax 2001;56:561-6. (Pubitemid 32588536)
    • (2001) Thorax , vol.56 , Issue.7 , pp. 561-566
    • Cox, G.1    Jones, J.L.2    Andi, A.3    Waller, D.A.4    O'Byrne, K.J.5
  • 9
    • 61549118453 scopus 로고    scopus 로고
    • Targeted therapies in lung cancer
    • Pirker R, Filipits M. Targeted therapies in lung cancer. Curr Pharm Des 2009;15:188-206.
    • (2009) Curr Pharm des , vol.15 , pp. 188-206
    • Pirker, R.1    Filipits, M.2
  • 11
    • 68949213744 scopus 로고    scopus 로고
    • Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer
    • Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009;28(Suppl 1): S32-7.
    • (2009) Oncogene , vol.28 , Issue.SUPPL. 1
    • Hirsch, F.R.1    Varella-Garcia, M.2    Cappuzzo, F.3
  • 12
    • 5644296647 scopus 로고    scopus 로고
    • Gefitinib ('Iressa,' ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: Tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone
    • Bailey R, Kris M, Wolf M, et al. Gefitinib ('Iressa,' ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone. Lung Canc 2003;41(Suppl 2):S71.
    • (2003) Lung Canc , vol.41 , Issue.SUPPL. 2
    • Bailey, R.1    Kris, M.2    Wolf, M.3
  • 17
    • 4644274700 scopus 로고    scopus 로고
    • Mutations and addiction to EGFR: The Achilles 'heal' of lung cancers?
    • DOI 10.1016/j.molmed.2004.08.008, PII S1471491404002163
    • Gazdar AF, Shigematsu H, Herz J, et al. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med 2004;10:481-6. (Pubitemid 39303620)
    • (2004) Trends in Molecular Medicine , vol.10 , Issue.10 , pp. 481-486
    • Gazdar, A.F.1    Shigematsu, H.2    Herz, J.3    Minna, J.D.4
  • 18
    • 44849093562 scopus 로고    scopus 로고
    • Oncogene addiction
    • discussion 80
    • Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68:3077-80; discussion 80.
    • (2008) Cancer Res , vol.68 , pp. 3077-3080
    • Weinstein, I.B.1    Joe, A.2
  • 19
    • 6344278732 scopus 로고    scopus 로고
    • Inherited predisposition to early onset lung cancer according to histological type
    • DOI 10.1002/ijc.20436
    • Li X, Hemminki K. Inherited predisposition to early onset lung cancer according to histological type. Int J Cancer 2004;112:451-7. (Pubitemid 39390610)
    • (2004) International Journal of Cancer , vol.112 , Issue.3 , pp. 451-457
    • Xinjun, L.I.1    Hemminki, K.2
  • 20
    • 41049089483 scopus 로고    scopus 로고
    • Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors
    • Regales L, Balak MN, Gong Y, et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One 2007;2:e810.
    • (2007) PLoS One , vol.2
    • Regales, L.1    Balak, M.N.2    Gong, Y.3
  • 21
    • 61549108338 scopus 로고    scopus 로고
    • EGFR T790M mutation: A double role in lung cancer cell survival?
    • Suda K, Onozato R, Yatabe Y, et al. EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 2009;4:1-4.
    • (2009) J Thorac Oncol , vol.4 , pp. 1-4
    • Suda, K.1    Onozato, R.2    Yatabe, Y.3
  • 23
    • 18244371651 scopus 로고    scopus 로고
    • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    • Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
    • (2005) PLoS Med , vol.2
    • Pao, W.1    Miller, V.A.2    Politi, K.A.3
  • 25
    • 33947287270 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib
    • DOI 10.1158/0008-5472.CAN-06-4293
    • Mulloy R, Ferrand A, Kim Y, et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007;67:2325-30. (Pubitemid 46424253)
    • (2007) Cancer Research , vol.67 , Issue.5 , pp. 2325-2330
    • Mulloy, R.1    Ferrand, A.2    Kim, Y.3    Sordella, R.4    Bell, D.W.5    Haber, D.A.6    Anderson, K.S.7    Settleman, J.8
  • 26
    • 0037674323 scopus 로고    scopus 로고
    • Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors
    • DOI 10.1074/jbc.M211158200
    • Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003;278:15435-40. (Pubitemid 36799884)
    • (2003) Journal of Biological Chemistry , vol.278 , Issue.17 , pp. 15435-15440
    • Blencke, S.1    Ullrich, A.2    Daub, H.3
  • 27
    • 68949209102 scopus 로고    scopus 로고
    • Overview of molecular testing in non-small-cell lung cancer: Mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors
    • John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009;28(Suppl 1):S14-23.
    • (2009) Oncogene , vol.28 , Issue.SUPPL. 1
    • John, T.1    Liu, G.2    Tsao, M.S.3
  • 29
    • 33846187218 scopus 로고    scopus 로고
    • Update on epidermal growth factor receptor mutations in non-small cell lung cancer
    • DOI 10.1158/1078-0432.CCR-06-0658
    • Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-41. (Pubitemid 46095394)
    • (2006) Clinical Cancer Research , vol.12 , Issue.24 , pp. 7232-7241
    • Riely, G.J.1    Politi, K.A.2    Miller, V.A.3    Pao, W.4
  • 30
    • 63049132774 scopus 로고    scopus 로고
    • First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
    • Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:1394-400.
    • (2009) J Clin Oncol , vol.27 , pp. 1394-1400
    • Inoue, A.1    Kobayashi, K.2    Usui, K.3
  • 31
    • 75249087060 scopus 로고    scopus 로고
    • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
    • Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
    • (2010) Lancet Oncol , vol.11 , pp. 121-128
    • Mitsudomi, T.1    Morita, S.2    Yatabe, Y.3
  • 32
    • 77953152895 scopus 로고    scopus 로고
    • A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study
    • Abstract 9 LBA
    • Inoue A, Kobayashi K, Maemondo M, et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. Eur J Cancer Suppl 2009;7:Abstract 9 LBA.
    • (2009) Eur J Cancer Suppl , pp. 7
    • Inoue, A.1    Kobayashi, K.2    Maemondo, M.3
  • 33
    • 72449160988 scopus 로고    scopus 로고
    • A randomized phase III study of gefinitib (IRESSATM) versus standard chemotherapy (gemcitabane plus cisplatin) as a first-line treatment for never smokers with advanced or metastatic adenocarcinoma of the lung
    • 13th World Conference on Lung Cancer. San Francisco
    • Lee J, Park K, Kim SW. A randomized phase III study of gefinitib (IRESSATM) versus standard chemotherapy (gemcitabane plus cisplatin) as a first-line treatment for never smokers with advanced or metastatic adenocarcinoma of the lung. 13th World Conference on Lung Cancer. San Francisco, J Thorac Oncol 2009;4(Suppl 1):S283-4.
    • (2009) J Thorac Oncol , vol.4 , Issue.SUPPL. 1
    • Lee, J.1    Park, K.2    Kim, S.W.3
  • 34
    • 33847323129 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations in lung cancer
    • Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
    • (2007) Nat Rev Cancer , vol.7 , pp. 169-181
    • Sharma, S.V.1    Bell, D.W.2    Settleman, J.3
  • 36
    • 42749085753 scopus 로고    scopus 로고
    • EGFR FISH versus mutation: Different tests, different end-points
    • Cappuzzo F. EGFR FISH versus mutation: different tests, different end-points. Lung Canc 2008;60:160-5.
    • (2008) Lung Canc , vol.60 , pp. 160-165
    • Cappuzzo, F.1
  • 37
    • 64249134715 scopus 로고    scopus 로고
    • Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)
    • Abstract 8038
    • Porta R, Queralt C, Cardenal F, et al. Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p). J Clin Oncol 2008;26:Abstract 8038.
    • (2008) J Clin Oncol , pp. 26
    • Porta, R.1    Queralt, C.2    Cardenal, F.3
  • 38
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
    • (2009) N Engl J Med , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 39
    • 67649431893 scopus 로고    scopus 로고
    • Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression
    • Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009;4:e5133.
    • (2009) PLoS One , vol.4
    • Rosell, R.1    Perez-Roca, L.2    Sanchez, J.J.3
  • 42
    • 20244389188 scopus 로고    scopus 로고
    • Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
    • Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501.
    • (2005) J Clin Oncol , vol.23 , pp. 2493-2501
    • Han, S.W.1    Kim, T.Y.2    Hwang, P.G.3
  • 43
    • 27244451321 scopus 로고    scopus 로고
    • Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
    • Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-37.
    • (2005) J Clin Oncol , vol.23 , pp. 6829-6837
    • Takano, T.1    Ohe, Y.2    Sakamoto, H.3
  • 44
    • 17844390172 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
    • Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68.
    • (2005) J Clin Oncol , vol.23 , pp. 2556-2568
    • Pao, W.1    Miller, V.A.2
  • 48
    • 33845265467 scopus 로고    scopus 로고
    • Impact of EGFR mutations on treatment of non-small cell lung cancer
    • Johnson BE, Jackman D, Janne PA. Impact of EGFR mutations on treatment of non-small cell lung cancer. Canc Chemother Pharmacol 2006;58(Suppl 7):5-9.
    • (2006) Canc Chemother Pharmacol , vol.58 , Issue.SUPPL. 7 , pp. 5-9
    • Johnson, B.E.1    Jackman, D.2    Janne, P.A.3
  • 49
    • 68949201629 scopus 로고    scopus 로고
    • Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors
    • Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28(Suppl 1):S24-31.
    • (2009) Oncogene , vol.28 , Issue.SUPPL. 1
    • Gazdar, A.F.1
  • 52
    • 23844444080 scopus 로고    scopus 로고
    • An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor
    • DOI 10.1158/0008-5472.CAN-05-1346
    • Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005;65:7096-101. (Pubitemid 41161238)
    • (2005) Cancer Research , vol.65 , Issue.16 , pp. 7096-7101
    • Kobayashi, S.1    Ji, H.2    Yuza, Y.3    Meyerson, M.4    Wong, K.-K.5    Tenen, D.G.6    Halmos, B.7
  • 53
    • 21144439000 scopus 로고    scopus 로고
    • Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
    • Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-70.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 7665-7670
    • Kwak, E.L.1    Sordella, R.2    Bell, D.W.3
  • 54
    • 49149118719 scopus 로고    scopus 로고
    • BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    • Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11.
    • (2008) Oncogene , vol.27 , pp. 4702-4711
    • Li, D.1    Ambrogio, L.2    Shimamura, T.3
  • 56
    • 70349684791 scopus 로고    scopus 로고
    • Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer
    • Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119:3000-10.
    • (2009) J Clin Invest , vol.119 , pp. 3000-3010
    • Regales, L.1    Gong, Y.2    Shen, R.3
  • 57
    • 47949114668 scopus 로고    scopus 로고
    • Detection of mutations in EGFR in circulating lung-cancer cells
    • Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.
    • (2008) N Engl J Med , vol.359 , pp. 366-377
    • Maheswaran, S.1    Sequist, L.V.2    Nagrath, S.3
  • 62
    • 21044445279 scopus 로고    scopus 로고
    • Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer
    • DOI 10.1158/1078-0432.CCR-04-1981
    • Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005;11:3750-7. (Pubitemid 40685592)
    • (2005) Clinical Cancer Research , vol.11 , Issue.10 , pp. 3750-3757
    • Chou, T.-Y.1    Chiu, C.-H.2    Li, L.-H.3    Hsiao, C.-Y.4    Tzen, C.-Y.5    Chang, K.-T.6    Chen, Y.-M.7    Perng, R.-P.8    Tsai, S.-F.9    Tsai, C.-M.10
  • 64
    • 19944426858 scopus 로고    scopus 로고
    • High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan
    • Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203.
    • (2004) Clin Cancer Res , vol.10 , pp. 8195-8203
    • Huang, S.F.1    Liu, H.P.2    Li, L.H.3
  • 66
    • 33746100318 scopus 로고    scopus 로고
    • Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer
    • DOI 10.1158/1078-0432.CCR-05-2324
    • Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006;12:3915-21. (Pubitemid 44078075)
    • (2006) Clinical Cancer Research , vol.12 , Issue.13 , pp. 3915-3921
    • Kimura, H.1    Kasahara, K.2    Kawaishi, M.3    Kunitoh, H.4    Tamura, T.5    Holloway, B.6    Nishio, K.7
  • 67
    • 84355160803 scopus 로고    scopus 로고
    • A Phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)
    • Lee CP, Taylor NJ, Attard G, et al. A Phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). MOGA/FRO Annual Scientific Meeting. Sanctuary Cove, Queensland, 2006:9-12.
    • MOGA/FRO Annual Scientific Meeting. Sanctuary Cove, Queensland, 2006 , pp. 9-12
    • Lee, C.P.1    Taylor, N.J.2    Attard, G.3
  • 69
    • 20244388126 scopus 로고    scopus 로고
    • Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
    • DOI 10.1200/JCO.2005.00.992
    • Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20. (Pubitemid 47050841)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.11 , pp. 2513-2520
    • Mitsudomi, T.1    Kosaka, T.2    Endoh, H.3    Horio, Y.4    Hida, T.5    Mori, S.6    Hatooka, S.7    Shinoda, M.8    Takahashi, T.9    Yatabe, Y.10
  • 77
    • 34249752278 scopus 로고    scopus 로고
    • Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer
    • PII 0124389420070100000006
    • Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with nonsmall cell lung cancer. J Thorac Oncol 2007;2:22-8. (Pubitemid 47163924)
    • (2007) Journal of Thoracic Oncology , vol.2 , Issue.1 , pp. 22-28
    • Yoshida, K.1    Yatabe, Y.2    Park, J.Y.3    Shimizu, J.4    Horio, Y.5    Matsuo, K.6    Kosaka, T.7    Mitsudomi, T.8    Hida, T.9
  • 78
    • 33746928318 scopus 로고    scopus 로고
    • Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer
    • Hsieh MH, Fang YF, Chang WC, et al. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 2006;53:311-22.
    • (2006) Lung Cancer , vol.53 , pp. 311-322
    • Hsieh, M.H.1    Fang, Y.F.2    Chang, W.C.3
  • 80
    • 38049008135 scopus 로고    scopus 로고
    • Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers
    • Savic S, Tapia C, Grilli B, et al. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer 2008;98:154-60.
    • (2008) Br J Cancer , vol.98 , pp. 154-160
    • Savic, S.1    Tapia, C.2    Grilli, B.3
  • 82
    • 24944497744 scopus 로고    scopus 로고
    • Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    • Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
    • (2005) J Clin Oncol , vol.23 , pp. 5900-5909
    • Eberhard, D.A.1    Johnson, B.E.2    Amler, L.C.3
  • 83
    • 20144387947 scopus 로고    scopus 로고
    • Predictors of the response to gefitinib in refractory non-small cell lung cancer
    • Kim KS, Jeong JY, Kim YC, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 2005;11:2244-51.
    • (2005) Clin Cancer Res , vol.11 , pp. 2244-2251
    • Kim, K.S.1    Jeong, J.Y.2    Kim, Y.C.3
  • 84
    • 50849094202 scopus 로고    scopus 로고
    • Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patients
    • Chang JW, Liu HP, Hsieh MH, et al. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients. Lung Cancer 2008;61:328-39.
    • (2008) Lung Cancer , vol.61 , pp. 328-339
    • Chang, J.W.1    Liu, H.P.2    Hsieh, M.H.3
  • 85
    • 45149084723 scopus 로고    scopus 로고
    • First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    • Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9.
    • (2008) J Clin Oncol , vol.26 , pp. 2442-2449
    • Sequist, L.V.1    Martins, R.G.2    Spigel, D.3
  • 86
    • 70350379181 scopus 로고    scopus 로고
    • Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: A population-based prospective study
    • Boldrini L, Ali G, Gisfredi S, et al. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. Oncol Rep 2009;22:683-91.
    • (2009) Oncol Rep , vol.22 , pp. 683-691
    • Boldrini, L.1    Ali, G.2    Gisfredi, S.3
  • 87
    • 65349165823 scopus 로고    scopus 로고
    • EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer
    • Smouse JH, Cibas ES, Jänne PA, et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009;117:67-72.
    • (2009) Cancer , vol.117 , pp. 67-72
    • Smouse, J.H.1    Cibas, E.S.2    Jänne, P.A.3
  • 88
    • 42049099467 scopus 로고    scopus 로고
    • Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis
    • DOI 10.1136/jcp.2007.051425
    • Smith GD, Chadwick BE, Willmore-Payne C, et al. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol 2008;61:487-93. (Pubitemid 351518232)
    • (2008) Journal of Clinical Pathology , vol.61 , Issue.4 , pp. 487-493
    • Smith, G.D.1    Chadwick, B.E.2    Willmore-Payne, C.3    Bentz, J.S.4
  • 89
    • 33750302365 scopus 로고    scopus 로고
    • Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib
    • DOI 10.1158/1078-0432.CCR-06-0714
    • Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:5764-9. (Pubitemid 44629607)
    • (2006) Clinical Cancer Research , vol.12 , Issue.19 , pp. 5764-5769
    • Kosaka, T.1    Yatabe, Y.2    Endoh, H.3    Yoshida, K.4    Hida, T.5    Tsuboi, M.6    Tada, H.7    Kuwano, H.8    Mitsudomi, T.9
  • 90
    • 74249106438 scopus 로고    scopus 로고
    • EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer
    • Mack PC, Holland WS, Burich RA, et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol 2009;4:1466-72.
    • (2009) J Thorac Oncol , vol.4 , pp. 1466-1472
    • Mack, P.C.1    Holland, W.S.2    Burich, R.A.3
  • 91
    • 77958185649 scopus 로고    scopus 로고
    • Consensus for EGFR mutation testing in non-small cell lung cancer: Results from a European workshop
    • Pirker R, Herth FJ, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010;5:1706-13.
    • (2010) J Thorac Oncol , vol.5 , pp. 1706-1713
    • Pirker, R.1    Herth, F.J.2    Kerr, K.M.3
  • 92
    • 37549002543 scopus 로고    scopus 로고
    • Isolation of rare circulating tumour cells in cancer patients by microchip technology
    • Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-9.
    • (2007) Nature , vol.450 , pp. 1235-1239
    • Nagrath, S.1    Sequist, L.V.2    Maheswaran, S.3
  • 94
    • 77951021505 scopus 로고    scopus 로고
    • Quantitative analysis of tumor in bronchial biopsy specimens
    • Coghlin CL, Smith LJ, Bakar S, et al. Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol 2010;5:448-52.
    • (2010) J Thorac Oncol , vol.5 , pp. 448-452
    • Coghlin, C.L.1    Smith, L.J.2    Bakar, S.3
  • 95
    • 76149086520 scopus 로고    scopus 로고
    • Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations
    • Garcia-Olivé I, Monsó E, Andreo F, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J 2010;35:391-5.
    • (2010) Eur Respir J , vol.35 , pp. 391-395
    • Garcia-Olivé, I.1    Monsó, E.2    Andreo, F.3
  • 96
    • 73449125505 scopus 로고    scopus 로고
    • Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis
    • Fassina A, Gazziero A, Zardo D, et al. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis. J Clin Pathol 2009;62:1096-102.
    • (2009) J Clin Pathol , vol.62 , pp. 1096-1102
    • Fassina, A.1    Gazziero, A.2    Zardo, D.3
  • 99
    • 79955879691 scopus 로고    scopus 로고
    • Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
    • Dufort S, Richard MJ, Lantuejoul S, et al. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res 2011;30:57.
    • (2011) J Exp Clin Cancer Res , vol.30 , pp. 57
    • Dufort, S.1    Richard, M.J.2    Lantuejoul, S.3
  • 100
    • 79955820904 scopus 로고    scopus 로고
    • Benchmarking of mutation diagnostics in clinical lung cancer specimens
    • Querings S, Altmüller J, Ansén S, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 2011;6:e19601.
    • (2011) PLoS One , vol.6
    • Querings, S.1    Altmüller, J.2    Ansen, S.3
  • 101
    • 33746789922 scopus 로고    scopus 로고
    • Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
    • DOI 10.1200/JCO.2005.05.4692
    • Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6. (Pubitemid 46638887)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.21 , pp. 3340-3346
    • Inoue, A.1    Suzuki, T.2    Fukuhara, T.3    Maemondo, M.4    Kimura, Y.5    Morikawa, N.6    Watanabe, H.7    Saijo, Y.8    Nukiwa, T.9
  • 102
    • 23844465454 scopus 로고    scopus 로고
    • Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp
    • DOI 10.1158/0008-5472.CAN-05-0331
    • Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276-82. (Pubitemid 41161259)
    • (2005) Cancer Research , vol.65 , Issue.16 , pp. 7276-7282
    • Nagai, Y.1    Miyazawa, H.2    Huqun3    Tanaka, T.4    Udagawa, K.5    Kato, M.6    Fukuyama, S.7    Yokote, A.8    Kobayashi, K.9    Kanazawa, M.10    Hagiwara, K.11
  • 103
    • 39649116928 scopus 로고    scopus 로고
    • EGFR tyrosine kinase inhibitors in lung cancer: An evolving story
    • DOI 10.1146/annurev.med.59.090506.202405
    • Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med 2008;59:429-42. (Pubitemid 351287947)
    • (2008) Annual Review of Medicine , vol.59 , pp. 429-442
    • Sequist, L.V.1    Lynch, T.J.2
  • 106
    • 58949089105 scopus 로고    scopus 로고
    • A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells
    • Molina-Vila MA, Bertran-Alamillo J, Reguart N, et al. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 2008;3:1224-35.
    • (2008) J Thorac Oncol , vol.3 , pp. 1224-1235
    • Molina-Vila, M.A.1    Bertran-Alamillo, J.2    Reguart, N.3
  • 107
    • 58949091382 scopus 로고    scopus 로고
    • An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients
    • Kawada I, Soejima K, Watanabe H, et al. An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. J Thorac Oncol 2008;3:1096-103.
    • (2008) J Thorac Oncol , vol.3 , pp. 1096-1103
    • Kawada, I.1    Soejima, K.2    Watanabe, H.3
  • 110
    • 36448978322 scopus 로고    scopus 로고
    • Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
    • Kim TY, Han SW, Bang YJ. Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Rev Mol Diagn 2007;7:821-36.
    • (2007) Expert Rev Mol Diagn , vol.7 , pp. 821-836
    • Kim, T.Y.1    Han, S.W.2    Bang, Y.J.3
  • 111
    • 51049110952 scopus 로고    scopus 로고
    • Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer
    • Fukui T, Ohe Y, Tsuta K, et al. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4751-7.
    • (2008) Clin Cancer Res , vol.14 , pp. 4751-4757
    • Fukui, T.1    Ohe, Y.2    Tsuta, K.3
  • 113
    • 63449103435 scopus 로고    scopus 로고
    • Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients
    • Yung TK, Chan KC, Mok TS, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009;15:2076-84.
    • (2009) Clin Cancer Res , vol.15 , pp. 2076-2084
    • Yung, T.K.1    Chan, K.C.2    Mok, T.S.3
  • 114
    • 84355164607 scopus 로고    scopus 로고
    • Direct detection of rare circulating tumor cells in blood by castPCR
    • Tan R, Brzoska P. Direct detection of rare circulating tumor cells in blood by castPCR. J Biomol Tech 2010;21(3 Suppl):S30.
    • (2010) J Biomol Tech , vol.21 , Issue.3 SUPPL.
    • Tan, R.1    Brzoska, P.2
  • 115
    • 65649128973 scopus 로고    scopus 로고
    • Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer
    • Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009;15:3023-8.
    • (2009) Clin Cancer Res , vol.15 , pp. 3023-3028
    • Yu, J.1    Kane, S.2    Wu, J.3
  • 116
    • 77958198161 scopus 로고    scopus 로고
    • Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: Immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations
    • Kato Y, Peled N, Wynes MW, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010;5:1551-8.
    • (2010) J Thorac Oncol , vol.5 , pp. 1551-1558
    • Kato, Y.1    Peled, N.2    Wynes, M.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.